株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コラゲナーゼ3:パイプライン製品の分析

Collagenase 3 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 363134
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
コラゲナーゼ3:パイプライン製品の分析 Collagenase 3 - Pipeline Review, H1 2020
出版日: 2020年04月30日 ページ情報: 英文 60 Pages
概要

当レポートでは、コラゲナーゼ3薬剤の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

コラゲナーゼ3の概要

治療薬の開発

コラゲナーゼ3:開発中の製品 - 開発段階別

コラゲナーゼ3:開発中の製品 - 治療範囲別

コラゲナーゼ3:開発中の製品 - 適応症別

コラゲナーゼ3:パイプライン製品の概況

  • 初期段階の製品

コラゲナーゼ3:企業で開発中の製品

コラゲナーゼ3:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

コラゲナーゼ3の治療薬開発に従事している企業

  • Paradigm Biopharmaceuticals Limited
  • Pfizer Inc.
  • 武田薬品工業

コラゲナーゼ3:薬剤プロファイル

コラゲナーゼ3:休止中のプロジェクト

コラゲナーゼ3:開発が中止された製品

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Aquilus Pharmaceuticals Inc, H1 2020
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
  • Pipeline by Pfizer Inc, H1 2020
  • Pipeline by Pharmahungary Group, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2399TDB

Summary:

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Collagenase 3 - Pipeline Review, H1 2020, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Knee Osteoarthritis, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
  • Aquilus Pharmaceuticals Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Pharmahungary Group
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
  • pentosan polysulfate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-152 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 21, 2020: Paradigm reports positive pre-IND meeting with US FDA
  • Feb 18, 2020: Paradigm reports: first patient dosed in USA under FDA approved expanded access program
  • Feb 13, 2020: Paradigm presents MPS VI poster at the World MPS Symposium in Orlando, Florida
  • Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
  • Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
  • Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
  • Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
  • May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
  • Apr 16, 2019: Paradigm's knee osteoarthritis study meets secondary endpoints
  • Feb 14, 2019: Paradigm's orphan phase 2/3 clinical program progresses
  • Nov 07, 2018: Paradigms Osteoarthritis treatment maintains more than 50% knee pain reduction
  • Sep 25, 2018: Paradigm consistently shows greater than 50% knee pain reduction
  • Aug 28, 2018: Paradigm's phase 2 a Ross River virus clinical trial recruitment finalised
  • Aug 15, 2018: Paradigm achieves 60% reduction in osteoarthritis pain
  • Aug 06, 2018: Paradigm achieves 100% recruitment in Phase 2b Osteoarthritis Trial
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer